A Phase 2/3 interventional study of Selinexor and Placebo in Dedifferentiated Liposarcoma, sponsored by Karyopharm Therapeutics Inc. Completed at 71 sites in 10 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-01-23.
Sponsored by Karyopharm Therapeutics Inc · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 101 studies in Liposarcoma with a site in United States — 23 open to participants now, 36 under way, 5 of them phase 3. Liposarcoma · United States.
Among the 101 studies in Liposarcoma with a site in United States, this one is the 7th largest by enrollment of the 92 interventional ones that give a count, is one of 5 that started in 2016, is one of 3 in phase 2/3, and was the 44th registered.
160 studies on the registry are indexed under Liposarcoma; 36 are open to participants now.
Browse Liposarcoma studies →23 of the 101 studies in Liposarcoma with a site in United States are open now. Recruiting first, the newest first:
Iovance Biotherapeutics, Inc. · Sites in United States
Ages 16–70
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Seattle Children's Hospital · Sites in United States
Ages 1–26
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Lamassu Bio Inc · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 29 Liposarcoma studies recruiting now, 20 (69%) set no upper age limit and 8 (28%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
101 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 57 · Phase 3 14
First in 1997; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 342 is above the median of 52 across 136 interventional studies indexed under Liposarcoma.
Median enrollment 44 across the 92 interventional studies, 149 across the 5 observational. Of the 59 that completed or were terminated, 35 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 101 have an industry lead sponsor. The 10 most frequent:
Karyopharm Therapeutics Inc is the lead sponsor of 37 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Karyopharm Therapeutics Inc has 1 study filed under Liposarcoma — fewer than ten, so there is no comparison to draw.
14 of the studies in Liposarcoma with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04031677Phase 3European Organisation for Research and Treatment of Cancer - EORTCSurgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | 2027-04-21 |
| NCT06881992Phase 3RezoluteA Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism | 2027-09 |
| NCT03114527Fox Chase Cancer CenterPhase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | 2026-12 |
| NCT02923778National Cancer Institute (NCI)Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery | 2026-12-29 |
| NCT06414434Michael Wagner, MDBTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma | 2027-01-15 |
Add all 14 to your calendar (.ics) → With an account.
Among the 101 studies in Liposarcoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 342 total patients will be randomized to study treatment (selinexor or placebo).
In the Phase 2 portion of the study, 57 patients were randomized to selinexor (60 mg) or placebo at a 1:1 allocation ratio.
In the Phase 3 portion of the study, approximately 285 patients will be randomized to selinexor (60 mg) or placebo with a 2:1 allocation ratio.
Patients who progress during the blinded portion of the study will be unblinded and if receiving:
Study treatment will be given twice-weekly on Day 1 and Day 3 during Weeks 1-6 of each six-week (42 day) cycle until disease progression or intolerability.
Treatment will continue until one or more of the following occurs:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a fixed blinding dose of 60 milligrams (mg) selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until progressive disease (PD).
Drug: Selinexor
Participants received a fixed blinding dose of 60 mg selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until PD.
Drug: Selinexor
Participants received a fixed blinding dose of placebo matched to selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until PD in double-blinded treatment period. Participants in the placebo group who had PD during the Phase 2 double-blinded treatment, will be elected to cross over to open-label selinexor.
Drug: Placebo
Participants received a fixed blinding dose of placebo matched to selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until PD or development of unacceptable toxicity. Participants in the placebo group who had PD during the Phase 3 double-blinded treatment, will be elected to cross over to open-label selinexor.
Drug: Placebo
Selinexor 60mg
Also known as: KPT-330
Also known as: sugar pill
Phase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
PFS was defined as the time from the date of randomization until the first date of Independent Review Committee (IRC)-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest sum of the longest diameter (SLD) recorded from baseline or the appearance of 1 or more new lesions.
Time frame: From the date of randomization until the first date of disease progression, or death due to any cause whichever occurred first (up to 57 months)
Phase 3 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1
PFS was defined as the time from the date of randomization in the Phase 3 open-label period until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
Time frame: From the date of randomization in the Phase 3 open label period until the first date of disease progression, or death due to any cause whichever occurred first (up to 57 months)
Phase 2 Double Blind: Progression-free Survival (PFS) as Per RECIST Version 1.1
PFS was defined as the time from date of randomization until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
Time frame: From date of randomization until the first date of PD or death due to any cause, whichever occurred first (up to 57 months)
Phase 2 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1
PFS was defined as the time from date of randomization in the Phase 2 open-label period until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
Time frame: From date of randomization in the Phase 2 open label period until the first date of PD or death due to any cause, whichever occurred first (up to 57 months)
Phase 3 Double Blind: Overall Survival (OS)
OS was defined as the duration (in months) from the date of randomization to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier.
Time frame: From date of randomization until death due to any cause, whichever occurred first (up to 70 months)
Phase 3 Open Label: Overall Survival (OS)
OS was defined as the duration (in months) from the date of randomization in the Phase 3 open-label period to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier.
Time frame: From date of randomization in phase 3 open label period until death due to any cause, whichever occurred first (up to 70 months)
Phase 2 Double Blind: Overall Survival (OS)
OS was defined as the duration (in months) from the date of randomization to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier.
Time frame: From the date of randomization until death due to any cause, whichever occurred first (up to 70 months)
Phase 2 Open Label: Overall Survival (OS)
OS was defined as the duration (in months) from the date of randomization in the Phase 2 open-label period to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier.
Time frame: From date of randomization in the Phase 2 open-label period until death due to any cause, whichever occurred first (up to 70 months)
Phase 3 Double Blind: Time-to-Progression (TTP) as Per RECIST Version 1.1
TTP was defined as the time from date of randomization until ICR-determined PD per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
Time frame: From date of randomization until the first date of PD or death due to any cause, whichever occurred first (up to 70 months)
Phase 3 Open Label: Time-to-Progression (TTP) as Per RECIST Version 1.1
TTP was defined as the time from date of randomization in the Phase 3 open-label period until ICR-determined PD per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
Time frame: From date of randomization in the Phase 3 open label period until the first date of PD or death due to any cause, whichever occurred first (up to 70 months)
Phase 2 Double Blind: Time-to-Progression (TTP) as Per RECIST Version 1.1
TTP was defined as the time from date of randomization until ICR-determined PD as per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
Time frame: From date of randomization until the first date of PD or death due to any cause, whichever occurred first (up to 70 months)
Phase 2 Open Label: Time-to-Progression (TTP) as Per RECIST Version 1.1
TTP was defined as the time from date of randomization in the Phase 2 open-label period until ICR-determined PD per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
Time frame: From date of randomization in the Phase 2 open-label period until the first date of PD or death due to any cause, whichever occurred first (up to 70 months)
Phase 3 Double Blind: Overall Response Rate (ORR)
ORR was defined as the percentage of participants who achieved complete response (CR) or partial response (PR), per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From date of randomization until the documentation of CR or PR (up to 70 months)
Phase 3 Open Label: Overall Response Rate (ORR)
ORR was defined as the percentage of participants who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From date of randomization in the Phase 3 open label period until the documentation of CR or PR (up to 70 months)
Phase 2 Double Blind: Overall Response Rate (ORR)
ORR was defined as the percentage of participants who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From date of randomization until the documentation of CR or PR (up to 70 months)
Phase 2 Open Label: Overall Response Rate (ORR)
ORR was defined as the percentage of participants who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From date of randomization in the Phase 2 open-label period until the documentation of CR or PR (up to 70 months)
Phase 3 Double Blind: Duration of Response (DOR)
DOR was defined as the time from first occurrence of CR or PR until the first date of PD per RECIST version 1.1 or death. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
Time frame: From first occurrence of CR or PR until the first date of PD (up to 70 months)
Phase 3 Double Blind: Progression-free Survival (PFS) as Per Investigator Assessment
PFS was defined as the time from date of randomization until the first date of PD, per RECIST version 1.1, or death due to any cause as defined by the Investigator based on clinical and/or radiologic criteria. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
Time frame: From the date of randomization until the first date of disease progression, or death due to any cause whichever occurred first (up to 70 months)
Phase 3 Double Blind: Time to Next Treatment (TTNT)
TTNT was defined as time since randomization until the first new antineoplastic therapy or death due to any cause, whichever occurs first.
Time frame: Time from randomization to the first new antineoplastic therapy or death due to any cause (up to 70 months)
Phase 2 Double Blind: Time to Next Treatment (TTNT)
TTNT was defined as time since randomization until the first new antineoplastic therapy or death due to any cause, whichever occurs first.
Time frame: Time from randomization to the first new antineoplastic therapy or death due to any cause (up to 70 months)
Phase 3 Double Blind: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.
Time frame: From start of study drug administration up to 70 months
Phase 3 Open Label: Number of Participants With TEAEs and Serious TEAEs
An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.
Time frame: From start of study drug administration up to 70 months
Phase 2 Double Blind: Number of Participants With TEAEs and Serious TEAEs
An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.
Time frame: From start of study drug administration up to 70 months
Phase 2 Open Label: Number of Participants With TEAEs and Serious TEAEs
An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.
Time frame: From start of study drug administration up to 70 months
Phase 3 Double Blind: Change From Baseline in Quality-of-life Questionnaire 30 Item (QLQ-C30)
The QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of patients with cancer. QLQ-C30 contains 30 questions that include five functional scales (physical, role, emotional, social, and cognitive functioning); three symptom scales (fatigue, nausea/vomiting and pain); six single-item symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties); and global health status/quality of life (QoL). Most questions used a 4-point scale (from 1 'Not at all' to 4 'Very much'); 2 questions used a 7-point scale (from 1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to a 0-100 scale. For the functional scales and the global health status/QoL, a higher score represents a better level of functioning (better health status); for the symptom scales/items, a higher score represents a higher level of symptomatology/problems (worse health status).
Time frame: Baseline up to Day 1387
Phase 3 Open Label: Change From Baseline in Quality-of-life Questionnaire 30 Item (QLQ-C30)
The QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of patients with cancer. QLQ-C30 contains 30 questions that include five functional scales (physical, role, emotional, social, and cognitive functioning); three symptom scales (fatigue, nausea/vomiting and pain); six single-item symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties); and global health status/quality of life (QoL). Most questions used a 4-point scale (from 1 'Not at all' to 4 'Very much'); 2 questions used a 7-point scale (from 1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to a 0-100 scale. For the functional scales and the global health status/QoL, a higher score represents a better level of functioning (better health status); for the symptom scales/items, a higher score represents a higher level of symptomatology/problems (worse health status).
Time frame: Baseline up to Day 379
The study was conducted at 71 sites in the United States, Canada, Germany, Belgium, Israel, United Kingdom, France, Spain, Italy, and Sweden. A total of 342 participants were enrolled, out of which 57 participants were randomized to receive study treatment in Phase 2 and 285 participants randomized, of which 284 participants received study treatment in Phase 3.
| Milestone | Phase 2 Double-blinded: Selinexor | Phase 2 Double-blinded: Placebo | Phase 3 Double-blinded: Selinexor | Phase 3 Double-blinded: Placebo | Phase 2 Open-label: Selinexor | Phase 3 Open-label: Selinexor |
|---|---|---|---|---|---|---|
| Started | 27 | 30 | 188 | 97 | 0 | 0 |
| Treated | 27 | 30 | 187 | 97 | 0 | 0 |
| Completed | 27 | 30 | 187 | 97 | 0 | 0 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Randomized but no treatment | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Phase 2 Double-blinded: Selinexor | Phase 2 Double-blinded: Placebo | Phase 3 Double-blinded: Selinexor | Phase 3 Double-blinded: Placebo | Phase 2 Open-label: Selinexor | Phase 3 Open-label: Selinexor |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 24 | 63 |
| Completed | 0 | 0 | 0 | 0 | 24 | 63 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
PFS was defined as the time from the date of randomization until the first date of Independent Review Committee (IRC)-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest sum of the longest diameter (SLD) recorded from baseline or the appearance of 1 or more new lesions.
| Months | Phase 3 Double-blinded: Selinexor | Phase 3 Double-blinded: Placebo |
|---|---|---|
| Phase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | 2.83 (2.73 to 4.11) | 2.07 (1.51 to 3.06) |
PFS was defined as the time from the date of randomization in the Phase 3 open-label period until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
| Months | Phase 3 Open Label: Selinexor |
|---|---|
| Phase 3 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1 | 2.73 (1.97 to 4.14) |
PFS was defined as the time from date of randomization until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
| Months | Phase 2 Double-blinded: Selinexor | Phase 2 Double-blinded: Placebo |
|---|---|---|
| Phase 2 Double Blind: Progression-free Survival (PFS) as Per RECIST Version 1.1 | 3.02 (1.41 to NA) | 2.76 (1.58 to NA) |
PFS was defined as the time from date of randomization in the Phase 2 open-label period until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
| Months | Phase 2 Open Label: Selinexor |
|---|---|
| Phase 2 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1 | 1.38 (1.38 to 2.27) |
OS was defined as the duration (in months) from the date of randomization to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier.
| Months | Phase 3 Double-blinded: Selinexor | Phase 3 Double-blinded: Placebo |
|---|---|---|
| Phase 3 Double Blind: Overall Survival (OS) | 10.38 (8.41 to 13.40) | 12.71 (8.54 to 15.90) |
OS was defined as the duration (in months) from the date of randomization in the Phase 3 open-label period to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier.
| Months | Phase 3 Open Label: Selinexor |
|---|---|
| Phase 3 Open Label: Overall Survival (OS) | 10.18 (5.78 to 14.69) |
OS was defined as the duration (in months) from the date of randomization to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier.
| Months | Phase 2 Double-blinded: Selinexor | Phase 2 Double-blinded: Placebo |
|---|---|---|
| Phase 2 Double Blind: Overall Survival (OS) | 17.31 (10.51 to 29.57) | 16.07 (8.38 to 23.06) |
OS was defined as the duration (in months) from the date of randomization in the Phase 2 open-label period to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier.
| Months | Phase 2 Open Label: Selinexor |
|---|---|
| Phase 2 Open Label: Overall Survival (OS) | 8.90 (4.96 to 18.92) |
TTP was defined as the time from date of randomization until ICR-determined PD per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
| Months | Phase 3 Double-blinded: Selinexor | Phase 3 Double-blinded: Placebo |
|---|---|---|
| Phase 3 Double Blind: Time-to-Progression (TTP) as Per RECIST Version 1.1 | 2.83 (2.73 to 4.11) | 2.10 (1.51 to 3.06) |
TTP was defined as the time from date of randomization in the Phase 3 open-label period until ICR-determined PD per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
| Months | Phase 3 Open Label: Selinexor |
|---|---|
| Phase 3 Open Label: Time-to-Progression (TTP) as Per RECIST Version 1.1 | 2.73 (1.97 to 4.14) |
TTP was defined as the time from date of randomization until ICR-determined PD as per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
| Months | Phase 2 Double-blinded: Selinexor | Phase 2 Double-blinded: Placebo |
|---|---|---|
| Phase 2 Double Blind: Time-to-Progression (TTP) as Per RECIST Version 1.1 | 3.02 (1.41 to NA) | 2.76 (1.58 to NA) |
TTP was defined as the time from date of randomization in the Phase 2 open-label period until ICR-determined PD per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
| Months | Phase 2 Open Label: Selinexor |
|---|---|
| Phase 2 Open Label: Time-to-Progression (TTP) as Per RECIST Version 1.1 | 1.38 (1.38 to 2.27) |
ORR was defined as the percentage of participants who achieved complete response (CR) or partial response (PR), per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Percentage of participants | Phase 3 Double-blinded: Selinexor | Phase 3 Double-blinded: Placebo |
|---|---|---|
| Phase 3 Double Blind: Overall Response Rate (ORR) | 2.7 (0.9 to 6.1) | 0 (NA to NA) |
ORR was defined as the percentage of participants who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Percentage of participants | Phase 3 Open Label: Selinexor |
|---|---|
| Phase 3 Open Label: Overall Response Rate (ORR) | 3.2 (0.4 to 11) |
ORR was defined as the percentage of participants who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Percentage of participants | Phase 2 Double-blinded: Selinexor | Phase 2 Double-blinded: Placebo |
|---|---|---|
| Phase 2 Double Blind: Overall Response Rate (ORR) | 0 (NA to NA) | 0 (NA to NA) |
ORR was defined as the percentage of participants who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Percentage of participants | Phase 2 Open Label: Selinexor |
|---|---|
| Participants who achieved CR | 0 |
| Participants who achieved PR | 0 |
DOR was defined as the time from first occurrence of CR or PR until the first date of PD per RECIST version 1.1 or death. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
| Months | Phase 3 Double-blinded: Selinexor | Phase 3 Double-blinded: Placebo |
|---|---|---|
| Phase 3 Double Blind: Duration of Response (DOR) | 7.39 (NA to NA) | — |
PFS was defined as the time from date of randomization until the first date of PD, per RECIST version 1.1, or death due to any cause as defined by the Investigator based on clinical and/or radiologic criteria. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
| Months | Phase 3 Double-blinded: Selinexor | Phase 3 Double-blinded: Placebo |
|---|---|---|
| Phase 3 Double Blind: Progression-free Survival (PFS) as Per Investigator Assessment | 2.89 (2.76 to 4.17) | 1.87 (1.45 to 2.89) |
TTNT was defined as time since randomization until the first new antineoplastic therapy or death due to any cause, whichever occurs first.
| Months | Phase 3 Double-blinded: Selinexor | Phase 3 Double-blinded: Placebo |
|---|---|---|
| Phase 3 Double Blind: Time to Next Treatment (TTNT) | 5.42 (4.67 to 6.34) | 3.22 (2.56 to 3.78) |
TTNT was defined as time since randomization until the first new antineoplastic therapy or death due to any cause, whichever occurs first.
| Months | Phase 2 Double-blinded: Selinexor | Phase 2 Double-blinded: Placebo |
|---|---|---|
| Phase 2 Double Blind: Time to Next Treatment (TTNT) | 4.96 (3.91 to 14.03) | 2.92 (2.04 to 5.06) |
An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.
| Participants | Phase 3 Double-blinded: Selinexor | Phase 3 Double-blinded: Placebo |
|---|---|---|
| Participants with TEAEs | 187 | 94 |
| Participants with Serious TEAEs | 73 | 18 |
An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.
| Participants | Phase 3 Open Label: Selinexor |
|---|---|
| Participants with TEAEs | 63 |
| Participants with Serious TEAEs | 25 |
An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.
| Participants | Phase 2 Double-blinded: Selinexor | Phase 2 Double-blinded: Placebo |
|---|---|---|
| Participants with TEAEs | 27 | 29 |
| Participants with Serious TEAEs | 4 | 6 |
An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.
| Participants | Phase 2 Open Label: Selinexor |
|---|---|
| Participants with TEAEs | 24 |
| Participants with Serious TEAEs | 13 |
The QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of patients with cancer. QLQ-C30 contains 30 questions that include five functional scales (physical, role, emotional, social, and cognitive functioning); three symptom scales (fatigue, nausea/vomiting and pain); six single-item symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties); and global health status/quality of life (QoL). Most questions used a 4-point scale (from 1 'Not at all' to 4 'Very much'); 2 questions used a 7-point scale (from 1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to a 0-100 scale. For the functional scales and the global health status/QoL, a higher score represents a better level of functioning (better health status); for the symptom scales/items, a higher score represents a higher level of symptomatology/problems (worse health status).
| Score on a Scale | Phase 3 Double-blinded: Selinexor | Phase 3 Double-blinded: Placebo |
|---|---|---|
| Global Health Status | 33.33 ± NA | — |
| Physical Functioning | 20.00 ± NA | — |
| Role Functioning | 16.67 ± NA | — |
| Emotional Functioning | 8.33 ± NA | — |
| Social Functioning | 50.00 ± NA | — |
| Cognitive Functioning | 0.00 ± NA | — |
| Fatigue | -22.22 ± NA | — |
| Nausea and Vomiting | 16.67 ± NA | — |
| Pain | 0.00 ± NA | — |
| Dyspnoea | 0.00 ± NA | — |
| Insomnia | 33.33 ± NA | — |
| Appetite Loss | 0.00 ± NA | — |
| Constipation | 0.00 ± NA | — |
| Diarrhoea | 33.33 ± NA | — |
| Financial Difficulties | -66.67 ± NA | — |
The QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of patients with cancer. QLQ-C30 contains 30 questions that include five functional scales (physical, role, emotional, social, and cognitive functioning); three symptom scales (fatigue, nausea/vomiting and pain); six single-item symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties); and global health status/quality of life (QoL). Most questions used a 4-point scale (from 1 'Not at all' to 4 'Very much'); 2 questions used a 7-point scale (from 1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to a 0-100 scale. For the functional scales and the global health status/QoL, a higher score represents a better level of functioning (better health status); for the symptom scales/items, a higher score represents a higher level of symptomatology/problems (worse health status).
| Score on a Scale | Phase 3 Open Label: Selinexor |
|---|---|
| Global Health Status | -16.67 ± NA |
| Physical Functioning | -40.00 ± NA |
| Role Functioning | -33.33 ± NA |
| Emotional Functioning | 0.00 ± NA |
| Social Functioning | -50.00 ± NA |
| Cognitive Functioning | -16.67 ± NA |
| Fatigue | 66.67 ± NA |
| Nausea and Vomiting | 0.00 ± NA |
| Pain | 0.00 ± NA |
| Dyspnoea | 0.00 ± NA |
| Insomnia | 0.00 ± NA |
| Appetite Loss | 0.00 ± NA |
| Constipation | 0.00 ± NA |
| Diarrhoea | 0.00 ± NA |
| Financial Difficulties | 100.00 ± NA |
Collected over From start of study drug administration up to 70 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 2 Double-blinded: Selinexor | 18/27 (66.7%) | 4/27 (14.8%) | 27/27 (100%) |
| Phase 2 Double-blinded: Placebo | 25/30 (83.3%) | 6/30 (20%) | 29/30 (96.7%) |
| Phase 3 Double-blinded: Selinexor | 127/187 (67.9%) | 73/187 (39%) | 186/187 (99.5%) |
| Phase 3 Double-blinded: Placebo | 67/97 (69.1%) | 18/97 (18.6%) | 94/97 (96.9%) |
| Phase 2 Open-label: Selinexor | 20/24 (83.3%) | 13/24 (54.2%) | 24/24 (100%) |
| Phase 3 Open-label: Selinexor | 43/63 (68.3%) | 25/63 (39.7%) | 62/63 (98.4%) |
| Event | Phase 2 Double-blinded: Selinexor | Phase 2 Double-blinded: Placebo | Phase 3 Double-blinded: Selinexor | Phase 3 Double-blinded: Placebo | Phase 2 Open-label: Selinexor | Phase 3 Open-label: Selinexor |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/27 | 0/30 | 4/187 | 0/97 | 3/24 | 0/63 |
| Small intestine obstructionGastrointestinal disorders | 0/27 | 1/30 | 2/187 | 2/97 | 2/24 | 2/63 |
| VomitingGastrointestinal disorders | 0/27 | 0/30 | 2/187 | 1/97 | 2/24 | 0/63 |
| PneumoniaInfections and infestations | 0/27 | 2/30 | 3/187 | 0/97 | 2/24 | 1/63 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/27 | 0/30 | 0/187 | 0/97 | 2/24 | 0/63 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/27 | 0/30 | 2/187 | 1/97 | 0/24 | 3/63 |
| AnaemiaBlood and lymphatic system disorders | 1/27 | 0/30 | 3/187 | 0/97 | 1/24 | 2/63 |
| Cardiac arrestCardiac disorders | 0/27 | 0/30 | 0/187 | 0/97 | 1/24 | 0/63 |
| Large intestine perforationGastrointestinal disorders | 0/27 | 1/30 | 0/187 | 0/97 | 1/24 | 0/63 |
| StomatitisGastrointestinal disorders | 0/27 | 0/30 | 0/187 | 0/97 | 1/24 | 0/63 |
| Event | Phase 2 Double-blinded: Selinexor | Phase 2 Double-blinded: Placebo | Phase 3 Double-blinded: Selinexor | Phase 3 Double-blinded: Placebo | Phase 2 Open-label: Selinexor | Phase 3 Open-label: Selinexor |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 24/27 | 10/30 | 151/187 | 38/97 | 20/24 | 45/63 |
| Decreased appetiteMetabolism and nutrition disorders | 15/27 | 5/30 | 144/187 | 21/97 | 14/24 | 32/63 |
| FatigueGeneral disorders | 15/27 | 14/30 | 96/187 | 31/97 | 18/24 | 33/63 |
| Weight decreasedInvestigations | 14/27 | 0/30 | 81/187 | 9/97 | 15/24 | 25/63 |
| AnaemiaBlood and lymphatic system disorders | 16/27 | 9/30 | 91/187 | 22/97 | 10/24 | 26/63 |
| VomitingGastrointestinal disorders | 15/27 | 4/30 | 93/187 | 12/97 | 14/24 | 31/63 |
| ThrombocytopeniaBlood and lymphatic system disorders | 11/27 | 2/30 | 72/187 | 5/97 | 11/24 | 24/63 |
| HyponatraemiaMetabolism and nutrition disorders | 9/27 | 6/30 | 52/187 | 8/97 | 10/24 | 11/63 |
| DiarrhoeaGastrointestinal disorders | 8/27 | 5/30 | 75/187 | 17/97 | 7/24 | 18/63 |
| ConstipationGastrointestinal disorders | 6/27 | 8/30 | 74/187 | 23/97 | 6/24 | 14/63 |
| Age, Categorical(Participants) | Phase 2 Double-blinded: Selinexor | Phase 2 Double-blinded: Placebo | Phase 3 Double-blinded: Selinexor | Phase 3 Double-blinded: Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 19 | 17 | 92 | 46 | 174 |
| >=65 years | 8 | 13 | 96 | 51 | 168 |
| Sex: Female, Male(Participants) | Phase 2 Double-blinded: Selinexor | Phase 2 Double-blinded: Placebo | Phase 3 Double-blinded: Selinexor | Phase 3 Double-blinded: Placebo | Total |
|---|---|---|---|---|---|
| Female | 12 | 11 | 74 | 33 | 130 |
| Male | 15 | 19 | 114 | 64 | 212 |
| Ethnicity (NIH/OMB)(Participants) | Phase 2 Double-blinded: Selinexor | Phase 2 Double-blinded: Placebo | Phase 3 Double-blinded: Selinexor | Phase 3 Double-blinded: Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 7 | 6 | 18 |
| Not Hispanic or Latino | 25 | 25 | 149 | 79 | 278 |
| Unknown or Not Reported | 0 | 2 | 32 | 12 | 46 |
| Race (NIH/OMB)(Participants) | Phase 2 Double-blinded: Selinexor | Phase 2 Double-blinded: Placebo | Phase 3 Double-blinded: Selinexor | Phase 3 Double-blinded: Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 5 | 9 | 3 | 19 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 2 | 0 | 3 |
| Black or African American | 1 | 2 | 3 | 1 | 7 |
| White | 23 | 20 | 139 | 80 | 262 |
| More than one race | 0 | 3 | 34 | 13 | 50 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jan 2016 to primary completion in Oct 2020, 57 months.
Results were first posted in Dec 2021, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selinexor